Novel Therapies and Drug Development for Tuberculosis
This session highlights new therapies and drug development for treating TB and multidrug-resistant TB (MDR-TB). Discussions will cover promising antibiotics, shorter treatment regimens, and innovative drug combinations. Attendees will gain insights into the latest clinical trials and the challenges of developing cost-effective, accessible TB treatments worldwide.
Related Conference of Novel Therapies and Drug Development for Tuberculosis
June 29-30, 2026
16th International Conference on Pulmonary & Respiratory Medicine
Aix-en-Provence, France
November 19-20, 2026
18th International Conference on Chronic Obstructive Pulmonary Disease
Dubai, UAE
Novel Therapies and Drug Development for Tuberculosis Conference Speakers
Recommended Sessions
- Community-based Approaches to TB and Lung Health Awareness
- Advances in Tuberculosis Diagnosis, Treatment, and Prevention
- Digital Health Technologies for Respiratory Disease Management
- Early Diagnosis and Biomarkers in Respiratory Diseases
- Emerging Respiratory Threats and Pandemic Preparedness
- Genetics and Susceptibility to Tuberculosis and Lung Diseases
- Global Efforts to Eliminate Tuberculosis by 2030
- Hospital-acquired Infections and Respiratory Care
- Impact of Smoking and Environmental Factors on Lung Health
- Latent Tuberculosis: Diagnosis, Treatment, and Control
- Lung Health: Emerging Trends and Challenges
- Multidrug-Resistant Tuberculosis (MDR-TB) and Novel Therapies
- Neonatal and Maternal Respiratory Health
- Novel Therapies and Drug Development for Tuberculosis
- Pediatric Tuberculosis and Respiratory Health
- Pulmonary Rehabilitation and Holistic Care for Respiratory Diseases
- Respiratory Infections and Global Public Health Concerns
- Respiratory Infections and Global Public Health Concerns
- Role of Artificial Intelligence in Tuberculosis Diagnosis
- Tuberculosis and HIV Co-infection: Challenges and Treatment
- Tuberculosis Prevention and Global Public Health Strategies
Related Journals
Are you interested in
- Advanced Lung Imaging - PULMONOLOGY 2026 (France)
- AI in Pulmonary Diagnostics - PULMONOLOGY 2026 (France)
- COPD Innovations - PULMONOLOGY 2026 (France)
- Critical Care Pulmonology - PULMONOLOGY 2026 (France)
- Digital Respiratory Health - PULMONOLOGY 2026 (France)
- Environmental Lung Diseases - PULMONOLOGY 2026 (France)
- Interstitial Lung Diseases - PULMONOLOGY 2026 (France)
- Interventional Pulmonology - PULMONOLOGY 2026 (France)
- Lung Cancer Biomarkers - PULMONOLOGY 2026 (France)
- Mechanical Ventilation Strategies - PULMONOLOGY 2026 (France)
- Pediatric Pulmonology - PULMONOLOGY 2026 (France)
- Precision Respiratory Medicine - PULMONOLOGY 2026 (France)
- Pulmonary Fibrosis Research - PULMONOLOGY 2026 (France)
- Pulmonary Hypertension - PULMONOLOGY 2026 (France)
- Pulmonary Rehabilitation - PULMONOLOGY 2026 (France)
- Respiratory Drug Delivery - PULMONOLOGY 2026 (France)
- Respiratory Infections - PULMONOLOGY 2026 (France)
- Severe Asthma Therapies - PULMONOLOGY 2026 (France)
- Sleep & Breathing Disorders - PULMONOLOGY 2026 (France)
- Thoracic Surgery Advances - PULMONOLOGY 2026 (France)